I-Mab

$59.66 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About I-Mab

I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Stock Analysis

last close $60.46
1-mo return -2.2%
3-mo return -14.7%
avg daily vol. 424.82T
52-week high 85.4
52-week low 37
market cap. $4.5B
forward pe -
annual div. -
roe -0.6%
ltg forecast 26%
dividend yield -
annual rev. $1.6B
inst own. 52.1%
baraka

Subscribe now for daily local and international financial news

Subscribe